Skip to main content
Top
Published in: Clinical Pharmacokinetics 8/2012

01-08-2012 | Review Article

Fundamentals of Population Pharmacokinetic Modelling

Modelling and Software

Authors: Tony K. L. Kiang, Catherine M. T. Sherwin, Michael G. Spigarelli, Dr Mary H. H. Ensom

Published in: Clinical Pharmacokinetics | Issue 8/2012

Login to get access

Abstract

Population pharmacokinetic modelling is widely used within the field of clinical pharmacology as it helps to define the sources and correlates of pharmacokinetic variability in target patient populations and their impact upon drug disposition. This review focuses on the fundamentals of population pharmacokinetic modelling and provides an overview of the commonly available software programs that perform these functions.
This review attempts to define the common, fundamental aspects of population pharmacokinetic modelling through a discussion of the literature describing the techniques and placing them in the appropriate context. An overview of the most commonly available software programs is also provided.
Population pharmacokinetic modelling is a powerful approach where sources and correlates of pharmacokinetic variability can be identified in a target patient population receiving a pharmacological agent. There is a need to further standardize and establish the best approaches in modelling so that any model created can be systematically evaluated and the results relied upon. Various nonlinear mixed-effects modelling methods, packaged in a variety of software programs, are available today. When selecting population pharmacokinetic software programs, the consumer needs to consider several factors, including usability (e.g. user interface, native platform, price, input and output specificity, as well as intuitiveness), content (e.g. algorithms and data output) and support (e.g. technical and clinical).
Literature
1.
go back to reference Jelliffe RW, Schumitzky A, Van Guilder M, et al. Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control. Ther Drug Monit 1993; 15: 380–93CrossRefPubMed Jelliffe RW, Schumitzky A, Van Guilder M, et al. Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control. Ther Drug Monit 1993; 15: 380–93CrossRefPubMed
3.
go back to reference Ette EI, Williams PJ. Population pharmacokinetics I: background, concepts, and models. Ann Pharmacother 2004; 38: 1702–6CrossRefPubMed Ette EI, Williams PJ. Population pharmacokinetics I: background, concepts, and models. Ann Pharmacother 2004; 38: 1702–6CrossRefPubMed
6.
go back to reference D’Argenio DZ. Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm 1981; 9: 739–56CrossRefPubMed D’Argenio DZ. Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm 1981; 9: 739–56CrossRefPubMed
7.
go back to reference Jelliffe RW, Gomis P, Schumitzky A. A population model of gentamicin made with a new nonparametric EM algorithm. Los Angeles (CA): Laboratory of Applied Pharmacokinetics, USC School of Medicine, 1990. Technical report no.: 90–4 Jelliffe RW, Gomis P, Schumitzky A. A population model of gentamicin made with a new nonparametric EM algorithm. Los Angeles (CA): Laboratory of Applied Pharmacokinetics, USC School of Medicine, 1990. Technical report no.: 90–4
8.
go back to reference Concordet D, Léger F, Ané C. Population PK/PD analysis. In: Chow S, editor. Encyclopedia of biopharmaceutical statistics. New York: Marcel Dekker, Inc., 2004 Concordet D, Léger F, Ané C. Population PK/PD analysis. In: Chow S, editor. Encyclopedia of biopharmaceutical statistics. New York: Marcel Dekker, Inc., 2004
9.
go back to reference Bustad A, Terziivanov D, Leary R, et al. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies. Clin Pharmacokinet 2006; 45: 365–83CrossRefPubMed Bustad A, Terziivanov D, Leary R, et al. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies. Clin Pharmacokinet 2006; 45: 365–83CrossRefPubMed
10.
go back to reference Jelliffe R, Schumitzky A, Van Guilder M. Population pharmacokinetics/pharmacodynamics modeling: parametric and nonparametric methods. Ther Drug Monit 2000; 22: 354–65CrossRefPubMed Jelliffe R, Schumitzky A, Van Guilder M. Population pharmacokinetics/pharmacodynamics modeling: parametric and nonparametric methods. Ther Drug Monit 2000; 22: 354–65CrossRefPubMed
11.
go back to reference Ogungbenro K, Aarons L. Design of population pharmacokinetic experiments using prior information. Xenobiotica 2007; 37: 1311–30CrossRefPubMed Ogungbenro K, Aarons L. Design of population pharmacokinetic experiments using prior information. Xenobiotica 2007; 37: 1311–30CrossRefPubMed
12.
go back to reference Tod M, Jullien V, Pons G. Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet 2008; 47: 231–43CrossRefPubMed Tod M, Jullien V, Pons G. Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet 2008; 47: 231–43CrossRefPubMed
13.
go back to reference Dartois C, Brendel K, Comets E, et al. Overview of model-building strategies in population PK/PD analyses: 2002–2004 literature survey. Br J Clin Pharmacol 2007; 64: 603–12CrossRefPubMedPubMedCentral Dartois C, Brendel K, Comets E, et al. Overview of model-building strategies in population PK/PD analyses: 2002–2004 literature survey. Br J Clin Pharmacol 2007; 64: 603–12CrossRefPubMedPubMedCentral
14.
go back to reference Pillai GC, Mentre F, Steimer JL. Non-linear mixed effects modeling-from methodology and software development to driving implementation in drug development science. J Pharmacokinet Pharmacodyn 2005; 32: 161–83CrossRefPubMed Pillai GC, Mentre F, Steimer JL. Non-linear mixed effects modeling-from methodology and software development to driving implementation in drug development science. J Pharmacokinet Pharmacodyn 2005; 32: 161–83CrossRefPubMed
15.
go back to reference Aarons L. Software for population pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 1999; 36: 255–64CrossRefPubMed Aarons L. Software for population pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 1999; 36: 255–64CrossRefPubMed
16.
go back to reference Bauer RJ, Guzy S, Ng C. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples. AAPS J 2007; 9: E60–83CrossRefPubMedPubMedCentral Bauer RJ, Guzy S, Ng C. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples. AAPS J 2007; 9: E60–83CrossRefPubMedPubMedCentral
17.
go back to reference Machado SG, Miller R, Hu C. A regulatory perspective on pharmacokinetic/pharmacodynamic modelling. Stat Methods Med Res 1999; 8: 217–45CrossRefPubMed Machado SG, Miller R, Hu C. A regulatory perspective on pharmacokinetic/pharmacodynamic modelling. Stat Methods Med Res 1999; 8: 217–45CrossRefPubMed
18.
go back to reference Aarons L, Balant LP, Mentre F, et al. Population approaches in drug development: report on an expert meeting to discuss population pharmacokinetic/pharmacodynamic software. Eur J Clin Pharmacol 1994; 46: 389–91CrossRefPubMed Aarons L, Balant LP, Mentre F, et al. Population approaches in drug development: report on an expert meeting to discuss population pharmacokinetic/pharmacodynamic software. Eur J Clin Pharmacol 1994; 46: 389–91CrossRefPubMed
19.
go back to reference Buffington DE, Lampasona V, Chandler MH. Computers in pharmacokinetics: choosing software for clinical decision making. Clin Pharmacokinet 1993; 25: 205–16CrossRefPubMed Buffington DE, Lampasona V, Chandler MH. Computers in pharmacokinetics: choosing software for clinical decision making. Clin Pharmacokinet 1993; 25: 205–16CrossRefPubMed
20.
go back to reference Charles BG, Duffull SB. Pharmacokinetic software for the health sciences: choosing the right package for teaching purposes. Clin Pharmacokinet 2001; 40: 395–403CrossRefPubMed Charles BG, Duffull SB. Pharmacokinetic software for the health sciences: choosing the right package for teaching purposes. Clin Pharmacokinet 2001; 40: 395–403CrossRefPubMed
21.
go back to reference Ette EI, Williams PJ. Population pharmacokinetics II: estimation methods. Ann Pharmacother 2004; 38: 1907–15CrossRefPubMed Ette EI, Williams PJ. Population pharmacokinetics II: estimation methods. Ann Pharmacother 2004; 38: 1907–15CrossRefPubMed
22.
go back to reference Dartois C, Lemenuel-Diot A, Laveille C, et al. Evaluation of uncertainty parameters estimated by different population PK software and methods. J Pharmacokinet Pharmacodyn 2007; 34: 289–311CrossRefPubMed Dartois C, Lemenuel-Diot A, Laveille C, et al. Evaluation of uncertainty parameters estimated by different population PK software and methods. J Pharmacokinet Pharmacodyn 2007; 34: 289–311CrossRefPubMed
23.
Metadata
Title
Fundamentals of Population Pharmacokinetic Modelling
Modelling and Software
Authors
Tony K. L. Kiang
Catherine M. T. Sherwin
Michael G. Spigarelli
Dr Mary H. H. Ensom
Publication date
01-08-2012
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 8/2012
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.1007/BF03261928

Other articles of this Issue 8/2012

Clinical Pharmacokinetics 8/2012 Go to the issue